Smooth muscle–specific expression of the smooth muscle myosin heavy chain gene in transgenic mice requires 5′-flanking and first intronic DNA sequence

CS Madsen, CP Regan, JE Hungerford… - Circulation …, 1998 - Am Heart Assoc
CS Madsen, CP Regan, JE Hungerford, SL White, I Manabe, GK Owens
Circulation research, 1998Am Heart Assoc
The smooth muscle myosin heavy chain (SM-MHC) gene encodes a major contractile
protein whose expression exclusively marks the smooth muscle cell (SMC) lineage. To
better understand smooth muscle differentiation at the transcriptional level, we have initiated
studies to identify those DNA sequences critical for expression of the SM-MHC gene. Here
we report the identification of an SM-MHC promoter-intronic DNA fragment that directs
smooth muscle–specific expression in transgenic mice. Transgenic mice harboring an SM …
Abstract
—The smooth muscle myosin heavy chain (SM-MHC) gene encodes a major contractile protein whose expression exclusively marks the smooth muscle cell (SMC) lineage. To better understand smooth muscle differentiation at the transcriptional level, we have initiated studies to identify those DNA sequences critical for expression of the SM-MHC gene. Here we report the identification of an SM-MHC promoter-intronic DNA fragment that directs smooth muscle–specific expression in transgenic mice. Transgenic mice harboring an SM-MHC-lacZ reporter construct containing ≈16 kb of the SM-MHC genomic region from −4.2 to +11.6 kb (within the first intron) expressed the lacZ transgene in all smooth muscle tissue types. The inclusion of the intronic sequence was required for transgene expression, since 4.2 kb of the 5′-flanking region alone was not sufficient for expression. In the adult mouse, transgene expression was observed in both arterial and venous smooth muscle, in airway smooth muscle of the trachea and bronchi, and in the smooth muscle layers of all abdominal organs, including the stomach, intestine, ureters, and bladder. During development, transgene expression was first detected in airway SMCs at embryonic day 12.5 and in vascular and visceral SMC tissues by embryonic day 14.5. Of interest, expression of the SM-MHC transgene was markedly reduced or absent in some SMC tissues, including the pulmonary circulation. Moreover, the transgene exhibited a heterogeneous pattern between individual SMCs within a given tissue, suggesting the possibility of the existence of different SM-MHC gene regulatory programs between SMC subpopulations and/or of episodic rather than continuous expression of the SM-MHC gene. To our knowledge, results of these studies are the first to identify a promoter region that confers complete SMC specificity in vivo, thus providing a system with which to define SMC-specific transcriptional regulatory mechanisms and to design vectors for SMC-specific gene targeting.
Am Heart Assoc